Top Biotech Companies in Vancouver (39)
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To...
Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel’s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are...
Cytel's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Private-equity ownership by Astorg and Nordic Capital is positioned as support to accelerate Cytel’s next phase of growth and innovation, signaling access to growth-oriented capital and sponsorship.
Product Line Growth: East Horizon launched as a cloud-based evolution of Cytel’s trial-design software and has continued adding modules through 2025, indicating ongoing investment and expansion of the software offering.
Market Expansion: Multiple acquisitions in 2022–2023 (e.g., Stève Consultants and co.faktor) and an increase in offices from 2021 to 2023 indicate broader geographic coverage and capability expansion, particularly across Europe.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API). #MadeBetter
From scientist features to #ScienceMemes and #SciComm ?Free educational videos and resources for Life Sciences? Check out our collection of free learning resources: https://info.abmgood.com/learning-resources Applied Biological Materials (abm) provides quality research reagents and custom services at incredible prices. We have an extensive product range to make abm your one-stop supplier for all your research needs: PCR, RT-PCR, qPCR, antibodies, siRNA, miRNA, CRISPR, stable...
Microbiome Insights, Inc. is a leading global provider of end-to-end services for microbiome DNA sequencing, including state-of-the-art bioinformatic analysis. The company's customized suite of services enables researchers and clinicians to easily and effectively include microbiome analysis in studies across a range of human, animal, agricultural, and environmental applications. The multidisciplinary team of researchers and knowledge leaders at the company's helm...
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid...
We are a Vancouver, Canada-based biotech firm focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe in vivo delivery of active gene editing machinery into target tissues. We have secured the exclusive worldwide...
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers...
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech...
Variational AI has developed Enki, the biopharma industry's first commercially-available foundation model for small molecules. Enki is based on a novel generative AI framework invented by Variational AI that has delivered novel and selective leads to multiple biopharma partners and customers.
WEX Pharmaceuticals Inc. is a late-stage drug development company in Vancouver, Canada dedicated to the research, development, manufacture, and commercialization of Halneuron®, a new novel non-opioid analgesic. Halneuron® is a highly selective sodium channel blocker and represents a breakthrough in painkiller technology: - Non-addictive, no withdrawal symptoms and no euphoria - No build of up of tolerance over time - A long duration of...
Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM). Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started. We are broadening our...
Dexcom's Top Stability & Growth Strengths
Strong Market Position & Advantage: Dexcom is repeatedly portrayed as a co-leader globally and the U.S. leader in CGM, supported by deep integrations with automated insulin delivery systems and a durable duopoly structure. This positioning reflects sustained adoption of its G7 platform and scale advantages.
Strong Revenue Growth: Recent results and guidance indicate consistent double-digit year-over-year growth with expanding margins. Management communications highlight ongoing momentum into 2026 supported by continued platform rollouts.
Market Expansion: The launch of an over-the-counter sensor and extended-wear G7 broaden addressable users beyond intensive insulin therapy. International uptake and clinical data in non‑insulin type 2 populations further extend the growth runway.
Mobcoder is a global technology company specializing in AI development and innovative solutions. Since 2014, we've launched over 300 apps, empowering businesses across various industries and locations.
SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a...
